A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma

Table 5 ALK mutations and their impact on the efficiency of ALK inhibitors

ALK mutation	Poorly effective	Effective	Highly effective	Reference
G1123S	Ceritinib			[118]
G1128A		Crizotinib, Ceritinib	Brigatinib, Lorlatinib, Alectinib	[119, 120]
L1151Tins	Crizotinib			[118]
L1152R	Crizotinib			[118]
C1156Y	Crizotinib			[118]
I1171N	Crizotinib	Ceritinib	Brigatinib, Lorlatinib, Alectinib	[118,119,120]
I1171T	Crizotinib, Alectinib	Ceritinib	Brigatinib, Lorlatinib, Alectinib	[119, 120]
F1174C	Ceritinib			[121]
F1174L	Crizotinib (partial inhibition)	Ceritinib	Brigatinib, Lorlatinib, Alectinib	[118,119,120,121]
F1174V	Crizotinib, Ceritinib			[118]
R1192P		Crizotinib, Ceritinib	Brigatinib, Lorlatinib, Alectinib	[119, 120]
L1196M	Crizotinib			[118]
L1198F	Lorlatinib			[118]
G1202R	Crizotinib, Ceritinib, Alectinib			[118]
S1206Y	Crizotinib			[118]
F1245V		Crizotinib, Ceritinib	Brigatinib, Lorlatinib	[119, 121]
F1245C	Crizotinib		Alectinib	[118, 120]
G1269A	Crizotinib	Ceritinib	Brigatinib, Lorlatinib, Alectinib	[118,119,120]
R1275Q		Crizotinib, Ceritinib	Brigatinib, Lorlatinib, Alectinib	[117, 119, 120]
Y1278S		Crizotinib, Ceritinib	Brigatinib, Lorlatinib, Alectinib	[119, 120]

ISSN: 1756-9966